Combined use of nivolumab and ipilimumab in Japanese patients with melanoma: a multicentre retrospective study of 111 cases

In Japanese patients with melanoma, the response rate of nivolumab plus ipilimumab (N/I) was lower than (35.1%) and the rate of adverse events was similar to (60.4%) those reported in previous clinical trials. No survival difference was observed with the use of N/I between clinical types. Patients who achieved a good response had better outcomes. Elevated lactate dehydrogenase level and having three or more metastatic sites were poor prognostic factors.